Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/320012
Type: Artigo de Periódico
Title: Skeletal Tumor Burden On Baseline 18f-fluoride Pet/ct Predicts Bone Marrow Failure After 223ra Therapy
Author: Etchebehere
EC; Araujo
JC; Milton
DR; Erwin
WD; Wendt
RE; Swanston
NM; Fox
P; Macapinlac
HA; Rohren
EM
Abstract: Purpose Determine if skeletal tumor burden on F-18-fluoride PET/CT (fluoride PET/CT) predicts the risk of bone marrow failure (BMF) after Ra-223 dichloride therapy (Ra-223). Methods Forty-one metastatic prostate cancer patients (43-89 years old; mean, 71 +/- 9 years.) underwent fluoride PET/CT prior to Ra-223. Bone marrow failure was the primary end point and was defined as (1) development of hematologic toxicity (World Health Organization grade 3 or 4) associated with no recovery after 6 weeks or (2) death due to BMF after the last Ra-223 dose. Bone marrow failure was correlated to fluoride PET/CT skeletal tumor burden (TLF10 [total lesion on fluoride PET/CT with SUVmax of 10 or greater]), use of chemotherapy, serum hemoglobin concentration, serum ALP, and serum prostate-specific antigen. Results The number of Ra-223 cycles ranged from 2 to 6 (mean, 5). Of the 41 patients, 16 developed BMF (G3 = 12; G4 = 4). A significantly increased risk of developing BMF was observed in patients with TLF10 of 12,000 or greater (hazard ratio [HR], 11.09; P < 0.0001), hemoglobin of less than 10 g/dL (HR, 7.35; P = 0.0002), and AP > 146 UI/L (HR, 4.52; P = 0.0100). Neither concomitant (HR, 0.91; P = 0.88) nor subsequent use of chemotherapy (HR, 0.14; P = 0.84) increased the risk of BMF, nor was prostate-specific antigen greater than 10 mu g/L (HR, 0.90; P = 0.86). Moreover, in a multivariable analysis, TLF10 was the only independent predictor of BMF (HR, 6.66; P = 0.0237). Conclusions Ra-223 was beneficial and reduced the risk of death even in patients with a high skeletal tumor burden. Fluoride PET/CT is able to determine which patients will benefit from Ra-223 and which will develop BMF.
Subject: Prostate Cancer
Skeletal Tumor Burden
Bone Metastases
Ra-223
Fluoride Pet/ct
Bone Marrow Failure
Editor: LIPPINCOTT WILLIAMS & WILKINS
Citation: Clinical Nuclear Medicine. LIPPINCOTT WILLIAMS & WILKINS, n. 41, n. 4, p. 268 - 273.
Rights: fechado
Identifier DOI: 10.1097/RLU.0000000000001118
Address: http://ovidsp.tx.ovid.com/sp-3.22.1b/ovidweb.cgi?QS2=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
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000372214500002.pdf304.11 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.